CEO / Founder
Miriam O’Reilly
Miriam O’Reilly, Founder of Haim Pharma Group, is a visionary leader driven by a deep passion for advancing innovative treatments for neurodegenerative diseases. With a Bachelor’s degree in Mechanical Engineering and a Master’s in Industrial Engineering Management, Miriam brings 20 years of proven expertise in establishing and leading operations and managing complex, high-stakes projects.
Her track record includes successfully navigating the intricate process of bringing EU GMP-certified medical cannabis to the UK market, demonstrating her ability to overcome regulatory, operational, and market-entry challenges with precision and determination. Her leadership reflects a combination of technical expertise and strategic insight, setting a strong foundation for Haim Pharma’s ambitious mission.
Miriam and her team are united in their belief that they can shape the future of neurodegenerative disease treatment. With their collective expertise and unwavering dedication, they are committed to creating innovative therapies that will transform patient care and improve lives worldwide.
Advisors
Dr Richard Bedlack, MD
Medical Advisor
- Stewart, Hughes, and Wendt Endowed Chair of ALS and Director of the Duke ALS Clinic.
- Distinguished neurologist and internationally recognized leader in ALS research and patient care.
- Co-founder of the Northeast ALS (NEALS) Consortium, advancing global ALS clinical studies.
- Led and participated in numerous multicenter ALS trials focused on disease progression and neuroprotection
- Renowned clinician-scientist and patient advocate, collaborating in NIH-funded consortia and the CDC
.
Mary Gulifoyle
Clinical Advisor
- Over 35 years of experience in biostatistics, clinical trial design, and regulatory submissions.
- qHeld senior biostatistics and clinical roles at J&J /Janssen Pharmaceuticals
- Contributed to multiple registrations programs in oncology, CNS, and rare diseases.
- Advised biotech companies on clinical strategy, trial design, and statistical oversight across all phases.
Dr. Keren Farin
IP Advisor
Dr. Karin Farin holds a Ph.D. in Neurobiology and is a certified Patent Attorney. With extensive experience in developing and managing intellectual property strategies for biomedical and biotechnology companies, she ensures that Haim Pharma’s innovations are strategically protected. Her dual expertise in neurobiology and IP law uniquely positions her to bridge scientific discovery and commercial success.
Haim Pharma Group pioneers the development and commercialization of psilocin-based treatments for neurodegenerative diseases.
Guided by a highly experienced team and advisory board, the company employs a strategic approach to drug development, ensuring excellence in regulatory navigation, clinical execution, and market entry.
This collective expertise positions Haim Pharma to successfully advance innovative solutions tailored to the needs of patients worldwide.
Collaborators
Collaboration is at the foundation of HPG. It provides rapid access to industry experts and cutting-edge facilities. This approach enhances flexibility and accelerates project timelines. It provides immediate access to essential infrastructure and experts. This allows us to leverage world-class resources.
Since our foundation in 2022, we have fostered strong collaborations with leading researchers in the field of neurodegenerative diseases. These strategic partnerships will enable us to execute comprehensive pharmaceutical product development, focusing on patient-specific treatments and scientifically-backed dosing strategies.
